The success of DP-b99 in the laboratory and in the clinic, thus far, has, in part, been attributed to the delicate manner by which it buffers and redistributes zinc ions (55)
For instance, semaglutide received FDA and EMA approval for cardiovascular risk reduction in patients with obesity in 2024, and Novo Nordisk are also targeting the use of semaglutide in patients with obesity-related heart failure and metabolic associated steatohepatitis (MASH, formerly known as fatty liver disease)
It is a tripeptide made of three specific amino acids: cysteine, glutamate, and glycine
CGM improves A1C and reduces hypoglycemia Insulin pump (CSII): Preferred for Type 1 patients on multiple daily injections failing glycemic targets
Patients with certain GLP1R variants may respond well to semaglutide alone, while those with stronger GIPR activation potential often show better outcomes with tirzepatide's dual-action approach